Samyang Biopharm was listed on the Korea Exchange (KOSPI) market on Monday. The number of shares listed is 7,435,870.

The listing was made through a direct listing following the spin-off from Samyang Holdings, the holding company of the Samyang Group, on Nov. 1. After the spin-off, Samyang Holdings shareholders will receive shares in both the existing company and the newly established company in proportion to their current holdings, meaning each shareholder's ownership percentage in the businesses remains unchanged. This process enables listing without a subscription.

With this listing, Samyang Biopharm can now have its growth potential and technological capabilities independently evaluated by the market, according to the company.

Moving forward, Samyang Biopharm plans to enhance corporate value by focusing on specialty products, including biodegradable sutures, gene delivery vectors, and anticancer drugs.

Samyang Biopharm developed Korea's first biodegradable surgical sutures in 1993 and now leads the global suture filament market. The company is also expanding its pharmaceutical business, focusing on anticancer drugs for seven solid tumors and five blood cancers.

Recently, it completed a cytotoxic anticancer injection factory with an annual capacity of 5 million vials and secured GMP certification in Japan and Europe. The company is accelerating next-generation drug development using its proprietary gene delivery system, SENS.

“This listing allows an independent evaluation of our technology and growth,” Samyang Biopharm CEO Kim Kyung-jin said. “We aim to enhance our corporate value and contribute to the group’s valuation.”